

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

J. Kevin Judice et al.

Title:

PHARMACEUTICAL COMPOSITIONS CONTAINING A GLYCOPEPTIDE ANTIBIOTIC AND A

CYCLODEXTRIN

Docket No.:

1343.016US1

Filed:

May 1, 2001

Examiner: Unknown

Serial No.: 09/846,893

Due Date: N/A

Group Art Unit: 1614

Commissioner for Patents Washington, D.C. 20231

We are transmitting herewith the following attached items (as indicated with an "X"):

 \underline{X} A return postcard.

X A Supplemental Information Disclosure Statement (2 pg.), Form 1449 (1 pg.), and copies of 8 cited references.

X PCT Search Report (8 pg.)

Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

Atty: Robert J. Harris, Ph.D.

Reg. No. 37,346

<u>CERTIFICATE UNDER 37 CFR 1.8:</u> The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this <u>Yellow</u> day of <u>April</u>, 2002.

Name

Alisia G. Dunbar

Signature

Customer Number 21186

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

(GENERAL)

S/N 09/846,893

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

J. Kevin Judice et al.

Serial No.:

09/846,893

Filed: Title:

May 1, 2001

PHARMACEUTICAL COMPOSITIONS CONTAINING A GLYCOPEPINDE

Examiner: Unknown

Group Art Unit: 1614

Docket: 1343.016US1

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

ANTIBIOTIC AND A CYCLODEXTRIN

MAY 0 6 2002

Assistant Commissioner for Patents Washington, D.C. 20231

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application.

Applicant is submitting herewith International Patent Application Publication Number WO 00/54751 (in German) with an English abstract included on the front page. This international document was cited in the international search report for the international counter-part application of the instant US application. This is a concise explanation of the relevance of International Patent Application Publication Number WO 00/54751 as it is presently understood and as required under 37 C.F.R. 1.98(a)(3). Accordingly, the Examiner is respectfully requested to acknowledge consideration of International Patent Application Publication Number WO 00/54751.

Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(c)(1) and 37 C.F.R. §1.97(e)(1), Applicants state that each item of information contained in the Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Supplemental Information Disclosure Statement.

It is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if a final action under §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in the application has been mailed, the Commissioner is hereby authorized to charge the required fees to Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT Scrial Number: 09/846,893	Dkt: 1948	Page 2 .016US1
Filing Date: May 1, 2001 <u>Title: PHARMACEUTICAL COMPOSITIONS CONTAINING A GLYCOPEPTIDE ANTIBIOTIC AND A CYCLODEXTRIN</u>	<u> </u>	
The Examiner is invited to contact the Applicants' Representatives at the telephone number if there are any questions regarding this communication.	H CE域TER 1600/2900 be	0
Respectfully submitted,	00/29	2002
J. KEVIN JUDICE ET AL.	8	
By their Representatives,		
SCHWEGMAN, LUNDBERG, WOESSNER & K P.O. Box 2938 Minneapolis, MN 55402 (612) 359-3265	LUTH,	P.A.
Date 4-30-02 By Robert J. Harris, Ph.D. Reg. No. 37,346	-	
CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Pater D.C. 20231, on this day of April, 2002. Alisia G. Dunbar	with the Uits, Washi	Jnited ngton,

*